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Summary A lymphocyte stimulation assay is described which detects immune reactivity to antigens derived
from the CaSki cervical carcinoma cell line. Taking a stimulation index of >4.1 as positive, the peripheral
blood lymphocytes of 14/20 patients (70%) with untreated dysplasia or carcinoma-in-situ, 8/19 patients (42%)
with untreated macroinvasive squamous cell carcinoma of the uterine cervix and 8/38 controls (21%) showed
positive reactions. Statistical analysis revealed a significant difference between the group of patients with
dysplasia or carcinoma-in-situ and the controls. The sera of patients and controls were simultaneously tested
for the presence of tumour-directed antibody. There was no correlation between the occurrence of cellular
immune reactivity and of serum antibody, both directed to cervical carcinoma antigens. Cellular immune
reactivity tended to occur more frequently in patients with preinvasive stages of cervical carcinoma, and
serum antibody in patients with macroinvasive carcinoma.
Dysplasia and carcinoma-in-situ are generally
considered to be preinvasive conditions of
squamous cell carcinoma of the uterine cervix
(Harris et al., 1980; Murphy & Coleman, 1976;
Noda et al., 1976; Shingleton et al., 1968). A
minority of these patients develop invasive
squamous cell carcinoma when not treated (Noda et
al., 1976). Diagnostic methods to detect which
lesions will progress to invasive carcinoma are not
available.
Immunosurveillance may be one of the
mechanisms which determine the progressive
potential of preinvasive lesions (Cochran, 1978;
DiSaia et al., 1972; loachim, 1976; Moore, 1978).
This prompted us to investigate immune reactivity
to antigens of cervical carcinoma cells in patients
with invasive and preinvasive stages of cervical
carcinoma. We previously reported on the
occurrence of antibodies directed to cervical
carcinoma cells. These antibodies were mainly
found in patients with macroinvasive stages of the
tumour (Van de Linde et al., 1981). Cellular
immune reactivity against antigens of cervical
carcinoma cells has been described in patients with
invasive disease (Cerni et al., 1979; Chen et al.,
1975; Chiang et al., 1976; DiSaia et al., 1972;
Goldstein et al., 1971; Mashiba et al., 1977; Pattillo
et al., 1977; Rivera et al., 1979; Wells et al., 1973).
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However, data in patients with dysplasia and
carcinoma-in-situ are conflicting (Chiang et al.,
1976; Mashiba et al., 1977; Rivera et al., 1979).
In this study we investigated the presence of
cellular immune reactivity to cervical carcinoma
cells both in patients with microinvasive cervical
carcinoma and in preinvasive disease. Furthermore
we looked for a relationship between the presence




Blood was obtained from patients with
macroinvasive and preinvasive stages (i.e.
carcinoma-in-situ and dysplasia) of carcinoma of
the uterine cervix. All invasive tumours were
classified histologically as squamous cell carcinoma
and staged according to the principles of the FIGO.
In all patients with preinvasive stages, cytology and
colposcopy was performed and the diagnosis was
confirmed histologically. None of the patients
received any form of treatment before the time of
blood sampling. The number of patients, median
age and age range for each group are given in
Table I.
Female patients with tumours other than
squamous cell carcinoma of the uterine cervix
served as controls; the tumours of these patients
were adenocarcinoma of the uterine cervix (5),
adenocarcinoma of the uterine corpus (3),
carcinoma of the colon (3), carcinoma of the breast
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Table I Occurrence of cellular immune reactivity and of serum antibody both directed to
antigens ofcervical carcinoma cells
Cellular immune reactivity Tumour-directed antibody*
median positive median positive
Diagnosis n age range n % n age range n %
Macroinvasive
cervical carcinoma:
advanced (II, III) 11 64 41-83 5 45 68 58 39-85 50 74
early (IB) 8 58 34-76 3 38 37 50 28-76 29 78
total macroinvasive 19 62 34-83 8 42 105 56 28-85 79 75
Preinvasive stages
carcinoma-in-situ/
dysplasia 12 34 23-50 7 58 46 35 23-68 7 15
mild-to-moderate
dysplasia 8 26 17-35 7 88 13 32 17-43 1 8
total preinvasive 20 32 17-50 14 70 59 35 17-68 8 14
Controls
other tumours 20 57 41-76 5 25 25 53 35-76 4 16
healthy controls 18 35 21-78 3 17 147 35 11-84 10 7
*All individuals tested for cellular immune reactivity were also assessed for the occurrence of
serum antibody; the groups tabulated under tumour-directed antibody include those listed under
cellular immune reactivity.
(5), fibrosarcoma (1), sarcoma (1), melanoma (2),
bronchial carcinoma (3), malignant teratoma of the
mediastinum (1), and thyroid carcinoma (1).
Additionally, blood was obtained from apparently
healthy female donors.
Cervical carcinoma cell cultures and controls
Cervical carcinoma cell lines used for this study
were the ME-180 cell line (Sykes et al., 1970) and
the CaSki cell line (Pattillo et al., 1977). Cultured
cells from the breast carcinoma cell line MCF-7
(Soule et al., 1973), from skin fibroblast cultures and
from amnion epithelial cells (all of human origin)
were used as controls.
Cells were cultured in 175cm2 plastic flasks
(Falcon) or 850cm2 plastic roller bottles (Falcon);
the culture medium consisted of Minimal Essential
Medium with Earle's salts (Gibco) buffered with
25mM HEPES and supplemented with 10%
heat-inactivated foetal calf serum (Gibco), 2mM
glutamine (Gibco), 100 I.Ul. ml-' penicillin and
100 ugml-' streptomycin.
Antigen preparation
Cell membrane antigen preparations were prepared
according to Patillo et al. (1977). Cells were
subcultured in PBS supplemented with 0.25%
trypsin 1:250 (Serva) and 0.5mM EDTA (Hayflick,
1973). Two or 3 days after subculturing the cells
were washed 3x in RPMI 1640 (Gibco) buffered
with 25mM HEPES and subsequently incubated in
this medium. After 24h, the culture fluid was
removed and centrifuged (10min, 2500g) to remove
non-adherent cells and cell-debris. The supernatant
was concentrated by membrane ultrafiltration under
nitrogen pressure (Amicon, YM1O membrane,
exclusion limit 10,000 dalton), centrifuged at
45,000g for 15min, sterilized by membrane
filtration (0.22pm, Millipore) and stored in small
aliquots at -30°C. After acid precipitation (Patt &
Grimes, 1974) the protein content was measured by
the Folin method (Oyama & Eagle, 1956).
Lymphocyte stimulation test
Mononuclear cells were isolated from heparinized
blood samples by Ficoll-Hypaque density gradient
centrifugation. The lymphocyte stimulation test was
performed in RPMI 1640, buffered with 0.2% (w/v)
bicarbonate and 25mM HEPES and supplemented
with 20% heat-inactivated (30min, 56°C) pooled
AB-serum, 2mM glutamine and antibiotics.
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plates (Nunc) and contained 50,ul antigen
preparation and 1004l cell suspension (final cell
concentration 1.3 x 106ml-1). Cell cultures were
incubated for 6 days at 37'C in humidified air with
5% CO2. Tumour and control antigens were used in
3 different concentrations (100, 50 and 25pgml-'
final concentration). Sixteen-18h before the end of
the incubation period 1 pCi (methyl-3H)-thymidine
(5 CimM, Radiochemical Centre, Amersham) was
added to each well. The cells were collected on
Titertek glass-fiber filters with a semi-automatic
harvester (Skatron). Air-dried filters were placed in
scintillation vials and 3ml toluene scintillator was
added. Radioactivity was measured with a Nuclear
Chicago Liquid Scintillation Counter (NC 725).
Stimulation with the T cell mitogen
phytohaemagglutinin (PHA; HA15, Wellcome,
40pgml-1 final concentration), and recall-antigens
candidine (Haarlem Allergen Laboratory, Haarlem,
the Netherlands, 10pgml-1 final concentration)
and varidase (Lederle, 2pgml-' final
concentration), was performed in each culture as
control for reactivity of the mononuclear cells.
Results were expressed as the mean counts per
minute (cpm) of quadruplicate cultures and as
stimulation index (SI=cpm of tumour antigen-
stimulated cultures . cpm of control antigen-
stimulated cultures). Data for optimal lymphocyte
stimulation are given; this was obtained for one of
the 3 antigen concentrations. The mean SI for
groups of patients is given in the text as a geometric
mean value.
Tumour-directed antibody
Antibodies to the cell membrane of ME-180 cervical
carcinoma cells were determined by indirect
immunofluorescence as described previously (Van
de Linde et al., 1981). Sera were considered positive
if the observed fluorescence remained after
absorption with pooled human tonsillar
lymphocytes.
Statistical analysis
The Kolmogorov-Smirnov one-sample test and the
Chi-square test were used.
Results
For the group of patients with macroinvasive
squamous cell carcinoma of the uterine cervix, data
(cpm) from stimulation of individual lymphocyte
preparations with antigen from the CaSki cell line
(optimal stimulation), antigen from amnion
epithelial cells and PHA are presented in Table II.
Antigen preparations of the ME-180 cell line gave
high cpm values in both patients and controls
Table II Lymphocyte stimulation assay with antigen from the CaSki line, with control antigen from
amnion epithelial cells and with PHA in patients with invasive squamous cell carcinoma of the uterine
cervix*
Advanced macroinvasive cervical carcinoma Early macroinvasive cervical carcinoma
CaSki Amnion PHA CaSki Amnion PHA
1,271 (468) 996 (560) 27,364 (4,660) 639 (238) 498 (210) 20,969 (2,112)
347 (164) 150 (100) 29,701 (10,007) 2,409 (1,190) 1,509 (867) 55,936 (3,260)
2,138 (728) 876 (351) 34,662 (4,739) 1,032 (246) 444 (183) 26,780 (4,021)
2,884 (1,437) 998 (339) 54,175 (12,582) 4,138 (1,474) 1,492 (669) 34,726 (2,038)
9,440 (3,366) 2,851 (2,154) 17,785 (2,505) 1,617 (483) 487 (193) 21,119 (5,119)
5,011 (1,480) 1,306 (694) 34,474 (5,036) 4,804 (1,738) 1,066 (206) 71,619 (12,183)
1,395 (401) 244 (102) 66,692 (7,308) 6,177 (1,099) 867 (689) 60,251 (2,120)
3,452 (311) 530 (214) 35,361 (3,036) 6,417 (884) 133 (55) 78,385 (7,549)
13,785 (5,947) 1,478 (1,249) 39,697 (8,011)
5,772 (776) 329 (278) 93,429 (7,143)
7,427 (843) 246 (143) 53,525 (11,236)
*Results in cpm of quadruplicate cultures (±s.d.).
order of stimulation indices (CaSki antigen).
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(results not shown): this mitogenic property of the
preparations rendered them unsuitable for
assessment of cellular immune reactivity to cervical
carcinoma cells. In the detection of antibodies to
cervical carcinoma cells optimal results were
obtained with ME-180 cells as target (Van de Linde
et al., 1981): due to the higher background
immunofluorescence, the percentage of sera positive
in the assay on CaSki cells was lower than that on
ME-180 cells. Cross-absorption experiments
indicated similar specificity of those sera positive
against both cervical carcinoma cell lines.
There was no significant response after lymphocyte
stimulation with the control antigens, including
antigens from human amnion cells (presented in
Table II; geometric mean stimulation index 1.09),
human fibroblasts and human breast carcinoma
cells. In the patients with cancer other than macro-
invasive squamous cell carcinoma of the uterine
cervix the control antigens gave similar results.
Because the largest amount of antigen could be
obtained from amnion epithelial cells, this
preparation served as control antigen. The mean
cpm of either stimulated cultures or control cultures
showed a large variation. Results were therefore
expressed as SI calculated with respect to amnion
antigen as control antigen. There was no
relationship between one particular antigen
concentration and optimal antigen concentration or
the value of optimal stimulation index.
Positive stimulation with PHA was observed in
all individuals tested; cpm data are given in Table II
for the group of macroinvasive cervical carcinoma
patients. In this group the geometric mean SI was
66 and the range, 16-590. In the group of patients
with carcinoma-in-situ or dysplasia the geometric SI
after PHA stimulation was 72 (range, 30-1244), in
the group of patients with other tumours, 43 (2-
260) and in the control group, 63 (22-151). In a
similar way, the various groups of patients and
controls did not differ in responsiveness to recall-
antigens candidine and varidase (data not shown).
There was no relation between the magnitude of the
response after mitogenic or recall-antigenic
stimulation and after CaSki carcinoma antigen
stimulation, being either expressed as cpm or as SI.
The results (SI) of the individual lymphocyte
cultures with CaSki cervical carcinoma antigen are
shown in Figure 1. In the control group of healthy
donors, the SI values were normally distributed
(Kolmogorov-Smirnov one-sample test). The
arithmetic mean SI +s.e. was 3.2+0.5 and the 95%
confidence interval, 2.3-4.1. From these data a
stimulation index of 4.1 or higher was considered to
be positive.
In Table I the frequency of positive lymphocyte
stimulation in the various patient groups is given.
Cultures from 8/19 (42%) patients with
macroinvasive cervical carcinoma were positive. In
the group of patients with other tumours 5/20
(25%) patients were positive. There was no obvious
association between positive stimulation and a
particular tumour. Highest individual stimulation
indices were found in the group of mild-to-
moderate dysplasia patients (Figure 1). Also, the
highest frequency (88%) of positive lymphocyte
stimulation was observed in this group and was
significantly higher than that in patients with
macroinvasive disease (42%), and both control
groups (P<0.01).
All patients and controls tested in the lymphocyte
stimulation assay were simultaneously assessed for
the presence of serum antibody. Data on the
relation with lymphocyte stimulation are
graphically presented in Figure 2. The frequency of
either positive lymphocyte stimulation or circulating
antibodies was 64% in patients with advanced and
61% with early macroinvasive carcinoma, 59% with
carcinoma-in-situ/severe dysplasia, 75% with mild-
to-moderate dysplasia, 25% in patients with other
tumours and 16% in the control donor group,
respectively. Both cellular immune reactivity as well
as serum antibody were detectable in 36% of
patients with advanced and 26% with early
macroinvasive cervical carcinoma, 16% with
carcinoma-in-situ/severe dysplasia, 14% with mild
to moderate dysplasia, and 5-6% of patients with
other tumours and the control donor group.
Discussion
In this study a lymphocyte stimulation assay with
the concentrated serum-free culture supernatant
from CaSki cervical carcinoma cells is described.
The highest frequency of a cellular immune
response in vitro to this antigen preparation was
found in untreated patients with mild-to-moderate
dysplasia (88%). The specificity of the cellular
immune response in vitro to cervical carcinoma cell-
associated antigens is clear from the low incidence
of positive results as well as the low magnitude of
individual responses in the group of patients with
tumours unrelated to squamous cervical cell
carcinoma and the group of healthy control donors:
the maximal stimulation index observed in these
groups was 9.6, whereas that in the patients with
invasive cervical carcinoma or preinvasive stages
was 48 (Tables I and II, Figure 1). The specificity of
the response can also be concluded from the
absence of stimulation by identically-prepared
control antigens. As the same results were obtained
with all control antigens it is unlikely that the
results with CaSki supernatants are due to
alloantigen stimulation.IMMUNE REACTIONS TO CERVICAL CARCINOMA CELLS 151
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Figure 2 Relation between the occurrence of circulating antibodies and cellular immune reactivity, both
directed to antigens of cervical carcinoma cells, in groups of patients with macroinvasive and preinvasive
stages of squamous cell carcinoma of the uterine cervix and in controls. In each column the frequency of
antibody (DE11) and positive lymphocyte stimulation (E) are presented: the simultaneous presence of cellular
immune reactivity and of serum antibody is indicated by S.
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The lower incidences of cellular immunity to the
CaSki antigen in the groups of cancer patients
(macroinvasive squamous cell carcinoma of the
uterine cervix or other tumours) may be ascribed
to immunological anergy occurring in patients with
advanced disease. However, (1) the results of
(positive) PHA and recall-antigen stimulation in all
groups, and (2) the absence of any relation between
positive lymphocyte stimulation by CaSki antigen
and by PHA or recall-antigen argues against this
explanation of the results (illustrated for PHA in
Table II).
We have previously found the presence of
antibody against cervical carcinoma cells mainly in
patients with macroinvasive cancer (Van de Linde
et al., 1981). In the present group of patients and
controls essentially the same results were obtained
(Table I). There was no relation between the
expression of a cellular immune response and the
detection of antibody, even though both were
putatively directed to antigens of cervical carcinoma
cells (Figure 2). This makes possible interference by
antibodies passively bound to mononuclear cell
(sub)populations in the lymphocyte stimulation test
unlikely. Inhibition by autologous serum has been
noted by Vanky et al. (1975) in lymphocyte
stimulation tests with autologous tumour cells in
cancer patients. From our data we conclude that
cellular immune reactivity and serum antibodies
occur in our patients with apparent mutual
exclusivity.
The highest frequency of cellular immune
reactivity was found in the group of patients with
preinvasive states (especially mild-to-moderate
dysplasia), whereas the group of patients with
macroinvasive stages of the tumour showed the
highest incidence of serum antibodies. This
divergence may be related to the in vivo role of
cellular- and antibody-mediated immune reactions
to tumour antigens (Cochran, 1978; DiSaia et al.,
1972; Ioachim, 1976; Moore, 1978). About two-
thirds of the patients with preinvasive stages of the
tumour were positive in the lymphocyte stimulation
test. A minority of these patients has been reported
to develop invasive cervical carcinoma if untreated
(about one third according to Noda et al., 1976). In
the context of the immunosurveillance theory it is
tempting to suggest a relationship between the
absence of cellular immune reactivity to the tumour
and the progression of preinvasive lesions to
invasive carcinoma. A possible role in vivo of
tumour-directed antibodies in tumour enhancement
has been hypothesized (Van de Linde et al., 1981).
To test these hypotheses follow-up studies are
needed; these are obviously impeded to the extent
that all patients with preinvasive and invasive
stages of cervical carcinoma receive treatment.
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